Kedudukan dalam Saham
#20654
Vaxart, Inc. operates as a biotechnology firm currently in the clinical... Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Harga Saham
$0.517
Disegerakkan terakhir: 2026-08-21
Perubahan (1 hari)
-0.58%
Perubahan (1 tahun)
47.71%
Perdagangan Vaxart, Inc. (VXRT)
Harga VXRT dengan permodalan pasaran b
Modal pasaran bagi Vaxart, Inc.(VXRT)
Modal Pasaran: $125.14M
Sehingga August 2026, Vaxart, Inc. mempunyai modal pasaran sebanyak $125.14M. Ini menjadikan Vaxart, Inc. syarikat ke-20654th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Vaxart, Inc. dari 1981 hingga 2026
VXRT berbanding dengan 5 teratas yang paling popular stocks
| Harga VXRT |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.211T
|
+4,164,442.00%
|
|
|
|
|
$4.547T
|
+3,633,324.35%
|
|
|
|
|
$4.162T
|
+3,326,244.06%
|
|
|
|
|
$3.593T
|
+2,870,993.60%
|
|
|
|
|
$2.793T
|
+2,231,743.37%
|
